Becton Dickinson Reports Stronger-Than-Expected Q1 Results, Affirms FY26 Guidance for 'New BD' Post-Separation

summarizeSummary

Becton Dickinson reported stronger-than-expected Q1 fiscal 2026 results, with revenue up 1.6% and reported EPS up 28.8%, and announced the expected closing of its strategic combination with Waters Corporation, affirming FY26 guidance for the 'New BD' entity.

check_boxKey Events

• Q1 Fiscal 2026 Financial Results

  Reported revenue of $5.252 billion increased 1.6% (0.4% FXN), and reported diluted EPS rose 28.8% to $1.34. Adjusted diluted EPS decreased 15.2% to $2.91, primarily due to purchase accounting, integration, and separation-related costs.

• Strategic Combination with Waters Corporation Expected to Close

  The combination of BD's Biosciences and Diagnostic Solutions business with Waters Corporation is expected to close today, marking a significant strategic milestone and pivot for the company towards 'New BD'.

• Affirmed FY26 Guidance for 'New BD'

  The company affirmed its full-year fiscal 2026 revenue growth guidance (low single-digit plus GAAP, low single-digit FXN) and provided adjusted diluted EPS guidance of $12.35 to $12.65 for the post-separation 'New BD' entity.

• Business Segment Reorganization Reflected

  The financial results reflect the company's reorganization into five distinct, separately-managed segments, effective October 1, 2025, with prior period amounts recast to align with the new structure, following a previous 8-K filing on February 5, 2026.

auto_awesomeAnalysis

Becton Dickinson & Co. reported its first fiscal quarter 2026 financial results, which were stronger than expected, and provided updated guidance for the 'New BD' entity following the expected closing of its Biosciences and Diagnostic Solutions business combination with Waters Corporation today. While reported revenue growth was modest, the significant increase in reported diluted EPS, despite a decline in adjusted diluted EPS due to non-recurring items, indicates underlying operational strength. The completion of the strategic combination with Waters Corporation marks a pivotal moment for the company, allowing it to intensify focus on its core medical technology businesses and drive long-term growth. Investors should monitor the performance of the newly structured 'New BD' against the affirmed guidance.